How many drugs treat Neurotrophic keratitis?

Drug Landscape tracks 3 marketed treatments for Neurotrophic keratitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neurotrophic-keratitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neurotrophic keratitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurotrophic keratitis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neurotrophic keratitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Oxervate	CENEGERMIN	Dompe farmaceutici s.p.a.	Recombinant Human Nerve Growth Factor [EPC]	High affinity nerve growth factor receptor	2017-01-01
Oxervate	Cenegermin-Bkbj	Dompe farmaceutici s.p.a.	Recombinant Human Nerve Growth Factor [EPC]	High affinity nerve growth factor receptor
Oxervate	Oxervate	Dompé Farmaceutici S.p.A		High affinity nerve growth factor receptor, Tumor necrosis factor receptor superfamily member 16

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Dompe farmaceutici s.p.a. · 2 drugs in Neurotrophic keratitis
Dompé Farmaceutici S.p.A · 1 drug in Neurotrophic keratitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neurotrophic keratitis:

Cite this brief

Drug Landscape (2026). Neurotrophic keratitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neurotrophic-keratitis. Accessed 2026-06-10.

Neurotrophic keratitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing